Syngene will gain its first U.S. facility in Baltimore. One of Maryland’s largest biotechnology companies will sell its Bayview facility for $36.5 million as part of a broader cost-cutting effort.

Emergent BioSolutions (NYSE:EBS) is selling its Baltimore-Bayview facility to contract research, development, and manufacturing organization Syngene International for $36.5M. The agreement includes a ...

Syngene is paying $36.5 million to acquire Emergent's shuttered biologics facility in the Bayview neighborhood of Baltimore, the Indian drugmaker said (PDF) Monday. Syngene ultimately plans to ...

Baltimore County District Judge Krystin Richardson on Tuesday made the ruling at a bail review hearing for William “Bill” ...

GAITHERSBURG, Md., March 10, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has entered into an agreement to sell its Baltimore-Bayview drug substance ...

Emergent BioSolutions sold its Baltimore-Bayview facility to Syngene International for $36.5 million, retaining future manufacturing rights. Emergent BioSolutions Inc. has completed the sale of ...

GAITHERSBURG, Md., March 19, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has completed the sale of its Baltimore-Bayview drug substance manufacturing ...